Latest news with #BauschHealthCompanies
Business Recorder
18 hours ago
- Business
- Business Recorder
TSX hits record high as investors assess economic data
Canada's main stock index inched up to an all-time high on Friday, but losses in heavyweight mining shares kept gains in check, while investors assessed domestic and US economic data. The S&P/TSX composite index was up 0.1% at 26,790.18 points, surpassing Tuesday's record intraday high of 26,780.19. Healthcare stocks led the sectoral gains with a 1.7% rise. Bausch Health Companies, the parent company of contact lens maker Bausch + Lomb, rose 3.1%. On the flip side, mining shares dropped 2.8%, tracking gold that fell to a near one-month low. TSX rises as US delays decision on direct Mideast involvement Gold miners were among the top losers with Lundin Gold falling 7% to the bottom of the main index. Kinross Gold lost 5.7%. Economic data on Friday showed Canada's economy contracted in April on a monthly basis as sectors exposed to tariffs negated a boost from services. The GDP figures are 'being driven by weaker exports to the US … I don't think that's being reflected in the market though,' said Philip Petursson, chief investment strategist at IG Wealth Management. 'It raises the potential for further interest rate cuts.' In the US, consumer spending unexpectedly fell in May, while monthly inflation increases remained moderate. Among individual stocks, TC Energy rose 3.3% after the pipeline operator started collecting tolls for the Southeast Gateway natural gas pipeline in Mexico. Miner Wesdome Gold finished its acquisition of Angus Gold. Shares of Wesdome Gold were down 2.9%.
Yahoo
02-05-2025
- Business
- Yahoo
Bausch Health Companies First Quarter 2025 Earnings: EPS Misses Expectations
Revenue: US$2.26b (up 4.9% from 1Q 2024). Net loss: US$58.0m (loss narrowed by 9.4% from 1Q 2024). US$0.16 loss per share (improved from US$0.17 loss in 1Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 7.9% growth forecast for the Pharmaceuticals industry in the US. Performance of the American Pharmaceuticals industry. The company's shares are down 3.3% from a week ago. You still need to take note of risks, for example - Bausch Health Companies has 1 warning sign we think you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-03-2025
- Business
- Yahoo
Shareholders in Bausch Health Companies (NYSE:BHC) are in the red if they invested three years ago
Investing in stocks inevitably means buying into some companies that perform poorly. But long term Bausch Health Companies Inc. (NYSE:BHC) shareholders have had a particularly rough ride in the last three year. Regrettably, they have had to cope with a 69% drop in the share price over that period. And more recent buyers are having a tough time too, with a drop of 25% in the last year. On the other hand, we note it's up 10.0% in about a month. Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business. Given that Bausch Health Companies didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally hope to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit. Over three years, Bausch Health Companies grew revenue at 5.4% per year. That's not a very high growth rate considering it doesn't make profits. It's likely this weak growth has contributed to an annualised return of 19% for the last three years. It can be well worth keeping an eye on growth stocks that disappoint the market, because sometimes they re-accelerate. After all, growing a business isn't easy, and the process will not always be smooth. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). If you are thinking of buying or selling Bausch Health Companies stock, you should check out this FREE detailed report on its balance sheet. Bausch Health Companies shareholders are down 25% for the year, but the market itself is up 9.4%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 9% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Bausch Health Companies better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Bausch Health Companies . We will like Bausch Health Companies better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
19-02-2025
- Business
- Yahoo
Bausch and Lomb's dealmaking CEO Brent Saunders: No deal for company is imminent
Listen and subscribe to Opening Bid on Apple Podcasts, Spotify, YouTube, or wherever you find your favorite podcasts. After completing $300 billion in healthcare deals over several decades, there is one deal Bausch and Lomb (BLCO) chairman and CEO Brent Saunders won't be making in 2025. The one for his contact lens maker with a history dating back to the 1800s. "No, I doubt it [if we restart the deal process]," Saunders told me on Yahoo Finance's Opening Bid podcast (video above; listen in below). "You can never say never, but, look, we have a big ambitious plan for 2025, and frankly, as I look at 2026 and 2027, it's even a bolder plan. And so we're heads down and focused on operating the business and driving the best results we can." Bausch and Lomb said earlier this month that it had explored taking the company private with a third-party buyer. No deal was reached, as a consortium of private equity firms including TPG (TPG) and Blackstone (BX) reportedly backed out. Bausch and Lomb said it would not pursue a transaction at this time. But it reiterated a view a full separation from Bausch Health Companies is still the goal. Bausch Health Companies owns 88.4% of Bausch and Lomb. Saunders believes interested buyers undervalued the company's product pipeline, which includes new technologies for contact lenses, dry eye relief, and surgical products. "There's always skepticism in R&D, and I expect that. But, there was definitely a deeper discount ascribed to our R&D pipeline, whether it be in pharma or contact lenses or surgical, or even consumer," Saunders explained. Saunders is known as one of the biggest dealmakers in the pharmaceutical industry of the past 15 years. In May 2013, during his first run as the CEO of Bausch and Lomb, he orchestrated its $8.7 billion sale to Valeant Pharmaceuticals. He then took over as the CEO of Forest Laboratories. By February 2014, Saunders orchestrated the sale of the company to Actavis for $25 billion. He assumed the CEO position. From there, in November 2014, he pulled off a $70 billion acquisition of Allergan and became its CEO. That's where Saunders's star quickly rose in media circles, overseeing the commercial success of botox and battling with feared activist investor Carl Icahn. Saunders then sold Allergan to Abbvie (ABBV) for $63 billion in a deal that closed in May 2020. He returned to Bausch and Lomb as CEO in March 2023. Today, Icahn's son Brett sits on the Bausch and Lomb board along with hedge fund titan John Paulson and Saunders. Bausch and Lomb's latest quarter underscored why Saunders is betting he could drive a higher valuation from a suitor later this year. The company's fourth quarter sales rose 9% from the prior year to $1.28 billion. Analysts had expected $1.25 billion. Growth was driven by the company's vision care segment, where contact lens growth increased by 17% in the US and 11% internationally. Adjusted earnings of $0.25 a share improved slightly year over year and beat Wall Street forecasts for $0.23 a share. Watch: What Bill Gates sees as the future of healthcare For the full year, Bausch and Lomb sees sales in a range of $4.95 billion to $5.05 billion. The Street was at $5.02 billion. The company forecast its dry-eye business to break $1 billion in sales this year, up from $916 million in 2024. Added Saunders, "Our scientists in-house created a new material that we're going to drive into clinical trials this year and potentially launch in 2027 which could be a breakthrough — a biomimetic lens that really mimics the biology of your eye in a contact lens. We're hoping the clinical trials will prove it out that it's healthier for your eye, but it's also much more comfortable for your eye and really potentially an upgrade to the standard of care of contact lenses in just a couple years." — Three times each week, I field insight-filled conversations and chats with the biggest names in business and markets on Opening Bid. You can find more episodes on our video hub or watch on your preferred streaming service. Brian Sozzi is Yahoo Finance's Executive Editor. Follow Sozzi on X @BrianSozzi, Instagram, and LinkedIn. Tips on stories? Email
